Atea Pharmaceuticals’ BEM/RZR combination hit a 93.91% sustained virologic response rate in its C-BEYOND Phase 3 trial against Epclusa’s 94.75%, a gap narrow enough to clear the non-inferiority bar across both primary and secondary endpoints in 905 patients. That result, announced in July and reinforced in this week’s quarterly update, is the clinical foundation Atea needs to file an NDA with the FDA, targeted for mid-2027, once C-FORWARD adds the pan-genotypic data.
The strategic bet behind BEM/RZR is not pure efficacy, since matching Epclusa’s historically high SVR rates is table stakes. The differentiation argument rests on drug-drug interaction risk and food effect. Roughly 80% of people living with HCV in the US take multiple concomitant medications for conditions like opioid use disorder, heart arrhythmia, heartburn, or gastroesophageal reflux disease (GERD), and interactions with existing approved therapies are a real clinical friction point. A regimen with a low DDI burden matters most in test-and-treat settings, where simplicity drives uptake. AbbVie’s Mavyret received an expanded indication in June 2025 covering both acute and chronic HCV, so BEM/RZR will enter a market with established competition, and the DDI profile will need to hold up in that comparison.
C-FORWARD is fully enrolled at more than 880 patients across 17 countries, with topline data expected in early 2027. That readout carries more weight than a simple confirmation: it needs to demonstrate efficacy across a broad range of HCV genotypes to support the pan-genotypic label that underpins the NDA. Approximately 47 million people worldwide are living with HCV, with new infections continuing to outpace annual cures, so the addressable population is not in question. The question is whether C-FORWARD’s genotype coverage data are broad enough to avoid a narrowed label.
The company also secured up to $200 million in non-dilutive funding from Hercules Capital, which provides runway without shareholder dilution while both pivotal readouts resolve. Meanwhile, AT-587 for chronic hepatitis E has completed single ascending dose work and is now conducting multiple ascending dose cohorts, with a proof-of-concept study planned for 2027. The C-FORWARD genotype coverage data, arriving in early 2027, is the single number that will determine whether the NDA timeline holds.
Source link: https://www.sec.gov/Archives/edgar/data/1593899/000119312526453636/d177149d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
